<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068885</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00009571</org_study_id>
    <nct_id>NCT02068885</nct_id>
  </id_info>
  <brief_title>Framingham State Food Study</brief_title>
  <acronym>(FS)2</acronym>
  <official_title>Dietary Composition and Energy Expenditure During Weight-Loss Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Framingham State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nutrition Science Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New Balance Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Many Voices Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blue Cross Blue Shield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of dietary composition on energy expenditure and chronic&#xD;
      disease risk factors, while also exploring physiological mechanisms underlying these effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many overweight and obese people can lose weight for a few months, but most have difficulty&#xD;
      maintaining weight loss over the long term. One explanation for the poor long-term outcome of&#xD;
      weight-loss diets relates to behavior, in that motivation to adhere to restrictive regimens&#xD;
      typically diminishes with time. An alternative explanation is that weight loss elicits&#xD;
      biological adaptations - specifically a decline in energy expenditure and an increase in&#xD;
      hunger - that promote weight regain. The purpose of this study is to evaluate the effects of&#xD;
      dietary composition on energy expenditure and risk for chronic diseases, while also exploring&#xD;
      physiological mechanisms underlying these effects. The study will be performed in&#xD;
      collaboration with Framingham State University, providing a novel and feasible method for&#xD;
      feeding subjects in dining halls and monitoring compliance.&#xD;
&#xD;
      Following 12±2% weight loss on a standard run-in diet, 150 adults (aged 18 to 65 years) will&#xD;
      be randomly assigned to one of three weight-loss maintenance diets controlled for protein&#xD;
      content (20% of energy) and varying widely in dietary carbohydrate-to-fat ratio:&#xD;
      Low-carbohydrate (20% of energy from carbohydrate, 60% fat), Moderate- carbohydrate (40%&#xD;
      carbohydrate, 40% fat), High-carbohydrate (60% carbohydrate, 20% fat). During the weight-loss&#xD;
      maintenance phase, energy intake will be adjusted to prevent changes in body weight. The&#xD;
      primary outcome will be change in total energy expenditure (indirect calorimetry using stable&#xD;
      isotopes) through 20 weeks. Secondary outcomes during weight maintenance will include resting&#xD;
      energy expenditure (indirect calorimetry using respiratory gas exchange), physical activity&#xD;
      (accelerometry), measures of insulin resistance and skeletal muscle work efficiency,&#xD;
      components of the metabolic syndrome, and hormonal and metabolic measures that might inform&#xD;
      an understanding of physiological mechanisms. We also will assess weight change during a&#xD;
      2-week ad libitum feeding phase, as an objective measure of dietary effects on hunger. The&#xD;
      analytic framework for addressing study hypothesis will be repeated-measures analysis of&#xD;
      variance, with adjustment for covariates (sex, race, ethnicity, age, anthropometrics, insulin&#xD;
      sensitivity and secretion, obesity-related genes). We also will test each covariate for&#xD;
      effect modification (covariate × diet interaction).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Energy Expenditure, Assessed by Indirect Calorimetry Using Stable Isotopes</measure>
    <time_frame>Start of Trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Total energy expenditure (TEE), assessed by indirect calorimetry using stable isotopes&#xD;
Total calories burned: Participants each drank about a cup of water containing special tracers which are measurable when they pass out of the body through urine. They provided a urine sample before they drank the water and then about every other day for the next two (2) weeks.&#xD;
Change: average (midpoint of test phase, end of test phase) - start of trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting Energy Expenditure, Assessed by Indirect Calorimetry Using Respiratory Gas Exchange</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Resting energy expenditure, assessed by indirect calorimetry using respiratory gas exchange Calories burned while resting: Participants lied down with head and neck under a clear plastic &quot;bubble,&quot; breathing room air. Gases in expired air were collected.&#xD;
Change: average (midpoint of test phase, end of test phase) - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity, Assessed by Accelerometry</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Actigraph Accelerometer Change: average (midpoint of test phase, end of test phase) - start of trial An Actigraph Accelerometer measures movement, similar to a pedometer. Data are reported as counts (divided by 1,000) per day. Each participant wore the the accelerometer on the right hip for 7 days at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal Muscle Work Efficiency</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Efficiency is expressed as percentage ratio of power generated during cycle ergometry (with conversion of Watts to kcal/min using a factor of 0.01433) to energy expenditure above resting.&#xD;
Change: end of test phase - start of trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin (Start of Trial)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
    <description>Leptin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 6) are expressed in percentage units (100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin (% Change)</measure>
    <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
    <description>Leptin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin (Start of Trial)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
    <description>Ghrelin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 8) are expressed in percentage units (100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin (% Change)</measure>
    <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
    <description>Ghrelin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,5-Anhydroglucitol</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Biomeasure of carbohydrate intake Change, 10 weeks: midpoint of test phase - start of trial Change, 20 weeks: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control, Assessed by HgA1c</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Change, 10 weeks: midpoint of test phase - start of trial. Change, 20 weeks: end of test phase - start of trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Triglyceride levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units Change, 10 weeks: midpoint of test phase - start of trial Change, 20 weeks: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition (DXA)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Body fat, presented as a % of total mass&#xD;
Participants each had a special scan (x-ray) to measure their amount of body fat. The special x-ray is called &quot;dual-energy x-ray absorptiometry&quot; (DXA). They were asked to lie still on a table for x-ray pictures.&#xD;
Change: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Glucose level, fasting blood draw Change: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipoprotein Particle Subfraction Distribution</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Lipoprotein insulin resistance (LPIR) score was calculated from triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (large/very large TRL-P, large HDL-P, small LDL-P). LPIR score is quantified on a scale of 0-100. Higher scores indicate worse outcome.&#xD;
Change: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Change: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>High-density lipoprotein cholesterol Change, 10 weeks: midpoint of test phase - start of trial. Change, 20 weeks: end of test phase - start of trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-HDL-cholesterol</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Calculated by subtracting HDL-cholesterol from total cholesterol. Change: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Low-density-lipoprotein cholesterol Change: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin (Start of Trial)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
    <description>Total and high molecular weight adiponectin Adiponectin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 20) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin (% Change)</measure>
    <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
    <description>Adiponeptin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (Start of Trial)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
    <description>C-reactive protein, marker of inflammation C-reactive protein levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 22) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (% Change)</measure>
    <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
    <description>C-reactive protein, marker of inflammation C-reactive protein levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 (Start of Trial)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
    <description>Interleukin-6, marker of inflammation Interleukin-6 levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 24) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 (% Change)</measure>
    <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
    <description>Interleukin-6, marker of inflammation Interleukin-6 levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Systolic and diastolic blood pressure Change: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen Activator Inhibitor-1 (Start of Trial)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
    <description>Plasminogen activator inhibitor-1 levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 27) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen Activator Inhibitor-1 (% Change)</measure>
    <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
    <description>Plasminogen activator inhibitor-1 levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Change: end of test phase - start of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity (Hepatic), Assessed by Frequently-sampled Oral Glucose Tolerance Test</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity (Systemic), Assessed by Frequently-sampled Oral Glucose Tolerance Test</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-esterified Fatty Acids</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ketones/Ketoacids</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Fuel Concentration in Serum (Glucose, Nonesterified Fatty Acids, Ketones/Ketoacids, Lactate)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid Stimulating Hormone</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroxine (T4)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse T3</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free T4</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like Growth Factor 1 (IGF-1)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF Binding Proteins</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Cortisol Excretion</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Catecholamine Excretion</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change During ad Libitum Feeding</measure>
    <time_frame>Ad libitum feeding period (weeks 21 and 22 following randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut Microbiome Profile</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Metabolomics Profile</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-reported Sleep Quality</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-reported Depression Measure</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Beck Depression Inventory-II [BDI-II]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-reported Mood/Anxiety</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Mood and Anxiety Symptom Questionnaire [MASQ]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-reported Food Addition Score</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Yale Food Addiction Scale [YFAS]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-reported Emotional Eating Score</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Emotional Eating Scale [EES]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-reported Binge Eating Score</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Binge Eating Scale [BES]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Function Related to Memory</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>California Verbal Learning Test - Second Edition [CVLT-II] and Digit Span Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Function Related to Processing Speed and Executive Function</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Trail Making Test Parts A and B [TMT-A, TMT-B]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Secretion Determined as Blood Insulin Concentration 30 Minutes After Oral Glucose (Start of Trial)</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
    <description>Insulin level 30 minutes after consuming 75 grams of glucose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect Modification by Insulin Secretion of Metabolic Responses to Diet</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
    <description>Effect modifier: Insulin level 30 minutes into an standard OGTT (Insulin-30) Outcome: Total Energy Expenditure Tertiles: Pre-weight-loss Insulin-30 (Low, Moderate, High) Change: average (midpoint of test phase, end of test phase) - start of trial</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect Modification by Insulin Resistance of Metabolic Responses to Diet</measure>
    <time_frame>Start of (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect Modification by Amylase Gene Copy Number</measure>
    <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Low carbohydrate diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate carbohydrate diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High carbohydrate diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Feeding study</intervention_name>
    <description>Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
    <arm_group_label>High carbohydrate diet</arm_group_label>
    <arm_group_label>Low carbohydrate diet</arm_group_label>
    <arm_group_label>Moderate carbohydrate diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 65 years&#xD;
&#xD;
          -  BMI ≥ 25 kg/m2&#xD;
&#xD;
          -  Weight ≤ 425 lbs&#xD;
&#xD;
          -  Medical clearance from a primary care provider&#xD;
&#xD;
          -  Plans to matriculate at Framingham State University (campus-based participants:&#xD;
             students), work on campus (campus-based participants: faculty and staff), or live in&#xD;
             the greater Framingham area (community-based participants) throughout the academic&#xD;
             year of enrollment in the study&#xD;
&#xD;
          -  Academic and social clearance from the FSU Office of Enrollment and Student&#xD;
             Development (student participants) or willingness to comply with Criminal Offender&#xD;
             Record Information (CORI) check and Sex Offender Registry Information (SORI) check&#xD;
             (community-based subjects)&#xD;
&#xD;
          -  Willingness to eat and drink only the foods and beverages on the study menus during&#xD;
             participation, with no food allergies or aversions&#xD;
&#xD;
          -  Willingness to eat in the dining hall&#xD;
&#xD;
          -  Willingness to abstain from consuming alcohol during participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Change in body weight exceeding ±10% during prior year&#xD;
&#xD;
          -  Recent adherence to a special diet&#xD;
&#xD;
          -  Recent adherence to a vigorous physical activity regimen (e.g., participation in a&#xD;
             varsity sport)&#xD;
&#xD;
          -  Chronic use of any medication or dietary supplement that could affect study outcomes&#xD;
&#xD;
          -  Current smoking (1 cigarette in the last week)&#xD;
&#xD;
          -  Heavy baseline alcohol consumption (&gt; 10 drinks/week) or history of binge drinking (≥&#xD;
             5 drinks in 1 day, anytime in past 6 months)&#xD;
&#xD;
          -  Physician diagnosis of a major medical/psychiatric illness or eating disorder&#xD;
&#xD;
          -  Abnormal HgA1c, TSH, BUN, creatinine; hematocrit &lt; 30; ALT &gt; 200% of normal upper&#xD;
             limit&#xD;
&#xD;
          -  Plans for a vacation during the study that would preclude adherence to prescribed diet&#xD;
&#xD;
          -  Additional exclusions for female participants: Irregular menstrual cycles; any change&#xD;
             in birth control medication during the 3 months prior to enrollment; pregnancy or&#xD;
             lactation during the 12 months prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Klein, MS, RD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cara B Ebbeling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David S Ludwig, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Framingham State University</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wong JM, Bielak L, Eddy RG, Stone L, Lakin PR, Sandman M, Devlin C, Seger-Shippee L, Wiroll D, Luoto PK, Klein GL, Ludwig DS, Ebbeling CB. An Academia-Industry Partnership for Planning and Executing a Community-Based Feeding Study. Curr Dev Nutr. 2018 Jul 5;2(9):nzy060. doi: 10.1093/cdn/nzy060. eCollection 2018 Sep.</citation>
    <PMID>30283914</PMID>
  </reference>
  <reference>
    <citation>Ebbeling CB, Klein GL, Luoto PK, Wong JMW, Bielak L, Eddy RG, Steltz SK, Devlin C, Sandman M, Hron B, Shimy K, Heymsfield SB, Wolfe RR, Wong WW, Feldman HA, Ludwig DS. A randomized study of dietary composition during weight-loss maintenance: Rationale, study design, intervention, and assessment. Contemp Clin Trials. 2018 Feb;65:76-86. doi: 10.1016/j.cct.2017.12.004. Epub 2017 Dec 9.</citation>
    <PMID>29233719</PMID>
  </reference>
  <reference>
    <citation>Ludwig DS, Greco KF, Ma C, Ebbeling CB. Testing the carbohydrate-insulin model of obesity in a 5-month feeding study: the perils of post-hoc participant exclusions. Eur J Clin Nutr. 2020 Jul;74(7):1109-1112. doi: 10.1038/s41430-020-0658-8. Epub 2020 May 20.</citation>
    <PMID>32435054</PMID>
  </reference>
  <results_reference>
    <citation>Ebbeling CB, Feldman HA, Klein GL, Wong JMW, Bielak L, Steltz SK, Luoto PK, Wolfe RR, Wong WW, Ludwig DS. Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial. BMJ. 2018 Nov 14;363:k4583. doi: 10.1136/bmj.k4583. Erratum in: BMJ. 2020 Nov 3;371:m4264.</citation>
    <PMID>30429127</PMID>
  </results_reference>
  <results_reference>
    <citation>Ebbeling CB, Bielak L, Lakin PR, Klein GL, Wong JMW, Luoto PK, Wong WW, Ludwig DS. Energy Requirement Is Higher During Weight-Loss Maintenance in Adults Consuming a Low- Compared with High-Carbohydrate Diet. J Nutr. 2020 Aug 1;150(8):2009-2015. doi: 10.1093/jn/nxaa150.</citation>
    <PMID>32470981</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <results_first_submitted>July 24, 2020</results_first_submitted>
  <results_first_submitted_qc>October 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2020</results_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>David S. Ludwig, MD, PhD</investigator_full_name>
    <investigator_title>Director, Obesity Prevention Center</investigator_title>
  </responsible_party>
  <keyword>Low carbohydrate diet</keyword>
  <keyword>Low fat diet</keyword>
  <keyword>Glycemic index</keyword>
  <keyword>Weight loss maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02068885/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02068885/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited participants by posting flyers, newspaper advertisements, and Internet announcements.</recruitment_details>
      <pre_assignment_details>We enrolled 234 participants for the run-in phase. Of these, 164 participants achieved at least 10% weight loss and were randomly assigned to one of three diets for the test phase (low-carbohydrate diet, n=57; moderate-carbohydrate diet, n=53; or high-carbohydrate diet, n=54).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Carbohydrate Diet</title>
          <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
        </group>
        <group group_id="P2">
          <title>Moderate Carbohydrate Diet</title>
          <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
        </group>
        <group group_id="P3">
          <title>High Carbohydrate Diet</title>
          <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Provided Data at Midpoint Test Phase</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Provided Data at End of Test Phase</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included in Intention-to-treat Analysis</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Carbohydrate Diet</title>
          <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
        </group>
        <group group_id="B2">
          <title>Moderate Carbohydrate Diet</title>
          <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
        </group>
        <group group_id="B3">
          <title>High Carbohydrate Diet</title>
          <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>pre-weight loss, beginning of run-in phase</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="13.3"/>
                    <measurement group_id="B2" value="37.3" spread="14.9"/>
                    <measurement group_id="B3" value="39.8" spread="15.1"/>
                    <measurement group_id="B4" value="37.8" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Energy Expenditure</title>
          <description>pre-weight loss, beginning of run-in phase</description>
          <units>kcal/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3110" spread="680"/>
                    <measurement group_id="B2" value="3030" spread="788"/>
                    <measurement group_id="B3" value="2915" spread="686"/>
                    <measurement group_id="B4" value="3021" spread="719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Energy Expenditure, Assessed by Indirect Calorimetry Using Stable Isotopes</title>
        <description>Total energy expenditure (TEE), assessed by indirect calorimetry using stable isotopes&#xD;
Total calories burned: Participants each drank about a cup of water containing special tracers which are measurable when they pass out of the body through urine. They provided a urine sample before they drank the water and then about every other day for the next two (2) weeks.&#xD;
Change: average (midpoint of test phase, end of test phase) - start of trial</description>
        <time_frame>Start of Trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Total Energy Expenditure, Assessed by Indirect Calorimetry Using Stable Isotopes</title>
          <description>Total energy expenditure (TEE), assessed by indirect calorimetry using stable isotopes&#xD;
Total calories burned: Participants each drank about a cup of water containing special tracers which are measurable when they pass out of the body through urine. They provided a urine sample before they drank the water and then about every other day for the next two (2) weeks.&#xD;
Change: average (midpoint of test phase, end of test phase) - start of trial</description>
          <population>Intention-to-treat analysis</population>
          <units>kcal/d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2713" lower_limit="2696" upper_limit="2730"/>
                    <measurement group_id="O2" value="2504" lower_limit="2486" upper_limit="2522"/>
                    <measurement group_id="O3" value="2640" lower_limit="2623" upper_limit="2657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="109" upper_limit="270"/>
                    <measurement group_id="O2" value="71" lower_limit="-12" upper_limit="155"/>
                    <measurement group_id="O3" value="-19" lower_limit="-104" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Energy Expenditure, Assessed by Indirect Calorimetry Using Respiratory Gas Exchange</title>
        <description>Resting energy expenditure, assessed by indirect calorimetry using respiratory gas exchange Calories burned while resting: Participants lied down with head and neck under a clear plastic &quot;bubble,&quot; breathing room air. Gases in expired air were collected.&#xD;
Change: average (midpoint of test phase, end of test phase) - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Energy Expenditure, Assessed by Indirect Calorimetry Using Respiratory Gas Exchange</title>
          <description>Resting energy expenditure, assessed by indirect calorimetry using respiratory gas exchange Calories burned while resting: Participants lied down with head and neck under a clear plastic &quot;bubble,&quot; breathing room air. Gases in expired air were collected.&#xD;
Change: average (midpoint of test phase, end of test phase) - start of trial</description>
          <population>Intention-to-treat analysis</population>
          <units>kcal/d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1615" lower_limit="1609" upper_limit="1621"/>
                    <measurement group_id="O2" value="1576" lower_limit="1569" upper_limit="1583"/>
                    <measurement group_id="O3" value="1603" lower_limit="1597" upper_limit="1609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="32" upper_limit="76"/>
                    <measurement group_id="O2" value="46" lower_limit="23" upper_limit="69"/>
                    <measurement group_id="O3" value="34" lower_limit="10" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Activity, Assessed by Accelerometry</title>
        <description>Actigraph Accelerometer Change: average (midpoint of test phase, end of test phase) - start of trial An Actigraph Accelerometer measures movement, similar to a pedometer. Data are reported as counts (divided by 1,000) per day. Each participant wore the the accelerometer on the right hip for 7 days at each time point.</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Activity, Assessed by Accelerometry</title>
          <description>Actigraph Accelerometer Change: average (midpoint of test phase, end of test phase) - start of trial An Actigraph Accelerometer measures movement, similar to a pedometer. Data are reported as counts (divided by 1,000) per day. Each participant wore the the accelerometer on the right hip for 7 days at each time point.</description>
          <population>Intention-to-treat analysis</population>
          <units>counts/d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495.8" lower_limit="489.5" upper_limit="502.1"/>
                    <measurement group_id="O2" value="463.8" lower_limit="457.0" upper_limit="470.6"/>
                    <measurement group_id="O3" value="476.6" lower_limit="470.4" upper_limit="482.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" lower_limit="-31.0" upper_limit="17.1"/>
                    <measurement group_id="O2" value="-42.4" lower_limit="-67.7" upper_limit="-17.1"/>
                    <measurement group_id="O3" value="-26.3" lower_limit="-52.0" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skeletal Muscle Work Efficiency</title>
        <description>Efficiency is expressed as percentage ratio of power generated during cycle ergometry (with conversion of Watts to kcal/min using a factor of 0.01433) to energy expenditure above resting.&#xD;
Change: end of test phase - start of trial.</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Muscle Work Efficiency</title>
          <description>Efficiency is expressed as percentage ratio of power generated during cycle ergometry (with conversion of Watts to kcal/min using a factor of 0.01433) to energy expenditure above resting.&#xD;
Change: end of test phase - start of trial.</description>
          <units>% power generated to energy expended</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="12.1" upper_limit="12.3"/>
                    <measurement group_id="O2" value="11.7" lower_limit="11.6" upper_limit="11.8"/>
                    <measurement group_id="O3" value="12.2" lower_limit="12.1" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.3" upper_limit="0.9"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.6" upper_limit="0.6"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.8" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leptin (Start of Trial)</title>
        <description>Leptin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 6) are expressed in percentage units (100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Leptin (Start of Trial)</title>
          <description>Leptin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 6) are expressed in percentage units (100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
          <population>Intention-to-treat analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="9.2" upper_limit="10.0"/>
                    <measurement group_id="O2" value="9.8" lower_limit="9.4" upper_limit="10.2"/>
                    <measurement group_id="O3" value="10.9" lower_limit="10.5" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leptin (% Change)</title>
        <description>Leptin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
        <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Leptin (% Change)</title>
          <description>Leptin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
          <population>Intention-to-treat analysis</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="7.7" upper_limit="29.1"/>
                    <measurement group_id="O2" value="34.8" lower_limit="22.6" upper_limit="48.2"/>
                    <measurement group_id="O3" value="34.2" lower_limit="21.8" upper_limit="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ghrelin (Start of Trial)</title>
        <description>Ghrelin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 8) are expressed in percentage units (100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Ghrelin (Start of Trial)</title>
          <description>Ghrelin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 8) are expressed in percentage units (100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
          <population>Intention-to-treat analysis</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="598.2" lower_limit="586.3" upper_limit="610.1"/>
                    <measurement group_id="O2" value="640.1" lower_limit="626.4" upper_limit="653.8"/>
                    <measurement group_id="O3" value="693.2" lower_limit="679.5" upper_limit="706.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ghrelin (% Change)</title>
        <description>Ghrelin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
        <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Ghrelin (% Change)</title>
          <description>Ghrelin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial</description>
          <population>Intention-to-treat analysis</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" lower_limit="-14.8" upper_limit="-8.6"/>
                    <measurement group_id="O2" value="-8.7" lower_limit="-12.0" upper_limit="-5.3"/>
                    <measurement group_id="O3" value="-4.9" lower_limit="-8.4" upper_limit="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1,5-Anhydroglucitol</title>
        <description>Biomeasure of carbohydrate intake Change, 10 weeks: midpoint of test phase - start of trial Change, 20 weeks: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>1,5-Anhydroglucitol</title>
          <description>Biomeasure of carbohydrate intake Change, 10 weeks: midpoint of test phase - start of trial Change, 20 weeks: end of test phase - start of trial</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="16.2" upper_limit="17.2"/>
                    <measurement group_id="O2" value="17.2" lower_limit="16.7" upper_limit="17.7"/>
                    <measurement group_id="O3" value="17.1" lower_limit="16.7" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, 10 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-3.0" upper_limit="-2.0"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-1.7" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.4" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, 20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-4.2" upper_limit="-2.8"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-2.6" upper_limit="-1.1"/>
                    <measurement group_id="O3" value="0.6" lower_limit="-0.2" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Control, Assessed by HgA1c</title>
        <description>Change, 10 weeks: midpoint of test phase - start of trial. Change, 20 weeks: end of test phase - start of trial.</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Control, Assessed by HgA1c</title>
          <description>Change, 10 weeks: midpoint of test phase - start of trial. Change, 20 weeks: end of test phase - start of trial.</description>
          <units>% hemoglobin with glucose bound</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" lower_limit="5.52" upper_limit="5.60"/>
                    <measurement group_id="O2" value="5.58" lower_limit="5.54" upper_limit="5.62"/>
                    <measurement group_id="O3" value="5.61" lower_limit="5.57" upper_limit="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, 10 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.02" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.00" upper_limit="0.06"/>
                    <measurement group_id="O3" value="-0.01" lower_limit="-0.05" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, 20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.04" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.03" upper_limit="0.04"/>
                    <measurement group_id="O3" value="-0.05" lower_limit="-0.08" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>Triglyceride levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units Change, 10 weeks: midpoint of test phase - start of trial Change, 20 weeks: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>Triglyceride levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units Change, 10 weeks: midpoint of test phase - start of trial Change, 20 weeks: end of test phase - start of trial</description>
          <units>md/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="71.1" upper_limit="84.0"/>
                    <measurement group_id="O2" value="76.5" lower_limit="70.2" upper_limit="83.3"/>
                    <measurement group_id="O3" value="80.5" lower_limit="74.2" upper_limit="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, 10 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" lower_limit="-18.5" upper_limit="-5.1"/>
                    <measurement group_id="O2" value="8.4" lower_limit="0.0" upper_limit="17.5"/>
                    <measurement group_id="O3" value="10.9" lower_limit="2.3" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, 20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" lower_limit="-19.8" upper_limit="-5.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-8.5" upper_limit="9.1"/>
                    <measurement group_id="O3" value="7.5" lower_limit="-1.7" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition (DXA)</title>
        <description>Body fat, presented as a % of total mass&#xD;
Participants each had a special scan (x-ray) to measure their amount of body fat. The special x-ray is called &quot;dual-energy x-ray absorptiometry&quot; (DXA). They were asked to lie still on a table for x-ray pictures.&#xD;
Change: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition (DXA)</title>
          <description>Body fat, presented as a % of total mass&#xD;
Participants each had a special scan (x-ray) to measure their amount of body fat. The special x-ray is called &quot;dual-energy x-ray absorptiometry&quot; (DXA). They were asked to lie still on a table for x-ray pictures.&#xD;
Change: end of test phase - start of trial</description>
          <population>Intention-to-treat analysis</population>
          <units>% of total body mass</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" lower_limit="34.6" upper_limit="37.9"/>
                    <measurement group_id="O2" value="37.3" lower_limit="35.1" upper_limit="39.5"/>
                    <measurement group_id="O3" value="37.8" lower_limit="36.2" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.7" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-0.7" upper_limit="0.1"/>
                    <measurement group_id="O3" value="-0.5" lower_limit="-1.0" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose</title>
        <description>Glucose level, fasting blood draw Change: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose</title>
          <description>Glucose level, fasting blood draw Change: end of test phase - start of trial</description>
          <population>Intention-to-treat analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="92.9" upper_limit="97.2"/>
                    <measurement group_id="O2" value="94.3" lower_limit="91.9" upper_limit="96.8"/>
                    <measurement group_id="O3" value="95.1" lower_limit="92.9" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-0.9" upper_limit="2.8"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-2.2" upper_limit="1.7"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-3.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipoprotein Particle Subfraction Distribution</title>
        <description>Lipoprotein insulin resistance (LPIR) score was calculated from triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (large/very large TRL-P, large HDL-P, small LDL-P). LPIR score is quantified on a scale of 0-100. Higher scores indicate worse outcome.&#xD;
Change: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipoprotein Particle Subfraction Distribution</title>
          <description>Lipoprotein insulin resistance (LPIR) score was calculated from triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (large/very large TRL-P, large HDL-P, small LDL-P). LPIR score is quantified on a scale of 0-100. Higher scores indicate worse outcome.&#xD;
Change: end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>score on a scale (0-100)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" lower_limit="28.7" upper_limit="40.5"/>
                    <measurement group_id="O2" value="31.5" lower_limit="26.1" upper_limit="36.9"/>
                    <measurement group_id="O3" value="31.4" lower_limit="26.9" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" lower_limit="-9.2" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-4.1" upper_limit="4.1"/>
                    <measurement group_id="O3" value="3.6" lower_limit="-0.6" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <description>Change: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>Change: end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.5" lower_limit="140.2" upper_limit="154.9"/>
                    <measurement group_id="O2" value="145.5" lower_limit="136.1" upper_limit="154.8"/>
                    <measurement group_id="O3" value="142.9" lower_limit="135.1" upper_limit="150.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="11.5" upper_limit="20.7"/>
                    <measurement group_id="O2" value="18.5" lower_limit="13.6" upper_limit="23.3"/>
                    <measurement group_id="O3" value="16.2" lower_limit="11.2" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL-cholesterol</title>
        <description>High-density lipoprotein cholesterol Change, 10 weeks: midpoint of test phase - start of trial. Change, 20 weeks: end of test phase - start of trial.</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>HDL-cholesterol</title>
          <description>High-density lipoprotein cholesterol Change, 10 weeks: midpoint of test phase - start of trial. Change, 20 weeks: end of test phase - start of trial.</description>
          <units>md/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="45.7" upper_limit="49.8"/>
                    <measurement group_id="O2" value="49.1" lower_limit="47.0" upper_limit="51.2"/>
                    <measurement group_id="O3" value="47.6" lower_limit="45.5" upper_limit="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, 10 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="9.4" upper_limit="12.8"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.1" upper_limit="8.7"/>
                    <measurement group_id="O3" value="4.7" lower_limit="2.9" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, 20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="11.0" upper_limit="15.0"/>
                    <measurement group_id="O2" value="9.7" lower_limit="7.6" upper_limit="11.8"/>
                    <measurement group_id="O3" value="6.8" lower_limit="4.7" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-HDL-cholesterol</title>
        <description>Calculated by subtracting HDL-cholesterol from total cholesterol. Change: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL-cholesterol</title>
          <description>Calculated by subtracting HDL-cholesterol from total cholesterol. Change: end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.5" lower_limit="94.1" upper_limit="108.9"/>
                    <measurement group_id="O2" value="99.0" lower_limit="90.6" upper_limit="107.5"/>
                    <measurement group_id="O3" value="98.2" lower_limit="91.2" upper_limit="105.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="1.8" upper_limit="10.9"/>
                    <measurement group_id="O2" value="11.0" lower_limit="6.3" upper_limit="15.8"/>
                    <measurement group_id="O3" value="9.5" lower_limit="4.6" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-cholesterol</title>
        <description>Low-density-lipoprotein cholesterol Change: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-cholesterol</title>
          <description>Low-density-lipoprotein cholesterol Change: end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" lower_limit="75.1" upper_limit="86.1"/>
                    <measurement group_id="O2" value="77.6" lower_limit="70.3" upper_limit="84.9"/>
                    <measurement group_id="O3" value="79.5" lower_limit="73.2" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="6.3" upper_limit="13.7"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7.8" upper_limit="15.7"/>
                    <measurement group_id="O3" value="8.2" lower_limit="4.2" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiponectin (Start of Trial)</title>
        <description>Total and high molecular weight adiponectin Adiponectin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 20) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin (Start of Trial)</title>
          <description>Total and high molecular weight adiponectin Adiponectin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 20) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.3" upper_limit="7.2"/>
                    <measurement group_id="O3" value="4.9" lower_limit="3.5" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Molecular Weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.4" upper_limit="3.5"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.6" upper_limit="4.2"/>
                    <measurement group_id="O3" value="2.7" lower_limit="1.9" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiponectin (% Change)</title>
        <description>Adiponeptin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
        <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin (% Change)</title>
          <description>Adiponeptin levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="24.9" upper_limit="42.9"/>
                    <measurement group_id="O2" value="17.4" lower_limit="9.4" upper_limit="26.0"/>
                    <measurement group_id="O3" value="23.0" lower_limit="14.5" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Molecular Weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="33.3" upper_limit="53.1"/>
                    <measurement group_id="O2" value="27.6" lower_limit="18.6" upper_limit="37.2"/>
                    <measurement group_id="O3" value="27.8" lower_limit="18.7" upper_limit="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein (Start of Trial)</title>
        <description>C-reactive protein, marker of inflammation C-reactive protein levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 22) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (Start of Trial)</title>
          <description>C-reactive protein, marker of inflammation C-reactive protein levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 22) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.6" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.7" upper_limit="4.6"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.6" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein (% Change)</title>
        <description>C-reactive protein, marker of inflammation C-reactive protein levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
        <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (% Change)</title>
          <description>C-reactive protein, marker of inflammation C-reactive protein levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" lower_limit="-24.2" upper_limit="7.1"/>
                    <measurement group_id="O2" value="-20.6" lower_limit="-33.8" upper_limit="-4.8"/>
                    <measurement group_id="O3" value="-1.7" lower_limit="-18.6" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6 (Start of Trial)</title>
        <description>Interleukin-6, marker of inflammation Interleukin-6 levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 24) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6 (Start of Trial)</title>
          <description>Interleukin-6, marker of inflammation Interleukin-6 levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 24) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.0" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.1" upper_limit="3.3"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.0" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6 (% Change)</title>
        <description>Interleukin-6, marker of inflammation Interleukin-6 levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
        <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6 (% Change)</title>
          <description>Interleukin-6, marker of inflammation Interleukin-6 levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.6" lower_limit="-35.4" upper_limit="-9.6"/>
                    <measurement group_id="O2" value="-20.1" lower_limit="-33.0" upper_limit="-4.7"/>
                    <measurement group_id="O3" value="-18.3" lower_limit="-31.8" upper_limit="-2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>Systolic and diastolic blood pressure Change: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Systolic and diastolic blood pressure Change: end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic, Start of trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.2" lower_limit="114.7" upper_limit="119.7"/>
                    <measurement group_id="O2" value="119.2" lower_limit="115.9" upper_limit="122.5"/>
                    <measurement group_id="O3" value="114.3" lower_limit="111.8" upper_limit="116.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic, Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-4.4" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-3.1" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.8" lower_limit="-1.3" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic, Start of trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" lower_limit="68.3" upper_limit="73.1"/>
                    <measurement group_id="O2" value="73.7" lower_limit="71.3" upper_limit="76.0"/>
                    <measurement group_id="O3" value="70.5" lower_limit="68.3" upper_limit="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic, Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="-0.4" upper_limit="4.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-1.3" upper_limit="4.1"/>
                    <measurement group_id="O3" value="2.2" lower_limit="-0.6" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasminogen Activator Inhibitor-1 (Start of Trial)</title>
        <description>Plasminogen activator inhibitor-1 levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 27) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Plasminogen Activator Inhibitor-1 (Start of Trial)</title>
          <description>Plasminogen activator inhibitor-1 levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)±exp(mean log)×(exp(SE log)-1)).&#xD;
Changes (see Outcome 27) are expressed in percentage units (100%×(exp(change in log)-1)): end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.7" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.7" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.2" lower_limit="0.6" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasminogen Activator Inhibitor-1 (% Change)</title>
        <description>Plasminogen activator inhibitor-1 levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
        <time_frame>Change through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Plasminogen Activator Inhibitor-1 (% Change)</title>
          <description>Plasminogen activator inhibitor-1 levels were log transformed for analysis. Change (expressed in percentage units, 100%×(exp(change in log)-1)): end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="-14.7" upper_limit="34.8"/>
                    <measurement group_id="O2" value="26.9" lower_limit="-0.2" upper_limit="61.4"/>
                    <measurement group_id="O3" value="14.9" lower_limit="-10.1" upper_limit="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrinogen</title>
        <description>Change: end of test phase - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrinogen</title>
          <description>Change: end of test phase - start of trial</description>
          <population>Retention rate was 90%, with 148 of 164 participants completing the study and 147 included in the analysis (after a priori exclusion of one participant who developed hypothyroidism).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.1" lower_limit="398.2" upper_limit="443.9"/>
                    <measurement group_id="O2" value="461.0" lower_limit="430.7" upper_limit="491.4"/>
                    <measurement group_id="O3" value="428.1" lower_limit="400.9" upper_limit="455.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" lower_limit="-36.8" upper_limit="2.7"/>
                    <measurement group_id="O2" value="-22.4" lower_limit="-43.2" upper_limit="-1.7"/>
                    <measurement group_id="O3" value="-21.7" lower_limit="-42.9" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity (Hepatic), Assessed by Frequently-sampled Oral Glucose Tolerance Test</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity (Systemic), Assessed by Frequently-sampled Oral Glucose Tolerance Test</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-esterified Fatty Acids</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Ketones/Ketoacids</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lactate</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Fuel Concentration in Serum (Glucose, Nonesterified Fatty Acids, Ketones/Ketoacids, Lactate)</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thyroid Stimulating Hormone</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thyroxine (T4)</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reverse T3</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free T4</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin-like Growth Factor 1 (IGF-1)</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IGF Binding Proteins</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Testosterone</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estradiol</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Luteinizing Hormone</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicle Stimulating Hormone</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Cortisol Excretion</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Catecholamine Excretion</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change During ad Libitum Feeding</title>
        <time_frame>Ad libitum feeding period (weeks 21 and 22 following randomization)</time_frame>
        <posting_date>12/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gut Microbiome Profile</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Metabolomics Profile</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-reported Sleep Quality</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-reported Depression Measure</title>
        <description>Beck Depression Inventory-II [BDI-II]</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-reported Mood/Anxiety</title>
        <description>Mood and Anxiety Symptom Questionnaire [MASQ]</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-reported Food Addition Score</title>
        <description>Yale Food Addiction Scale [YFAS]</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-reported Emotional Eating Score</title>
        <description>Emotional Eating Scale [EES]</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-reported Binge Eating Score</title>
        <description>Binge Eating Scale [BES]</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Function Related to Memory</title>
        <description>California Verbal Learning Test - Second Edition [CVLT-II] and Digit Span Test</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Function Related to Processing Speed and Executive Function</title>
        <description>Trail Making Test Parts A and B [TMT-A, TMT-B]</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Secretion Determined as Blood Insulin Concentration 30 Minutes After Oral Glucose (Start of Trial)</title>
        <description>Insulin level 30 minutes after consuming 75 grams of glucose</description>
        <time_frame>Start of trial (time of randomization, post-weight loss)</time_frame>
        <population>Descriptive data, reflecting participant flow Pre-weight loss (N=162, minus 1 participant in the Moderate carbohydrate diet group for whom insulin-30 result is missing) Start of trial (N=162) End of test phase (N=148, minus 1 participant in the High carbohydrate diet group for whom insulin-30 result is missing)</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion Determined as Blood Insulin Concentration 30 Minutes After Oral Glucose (Start of Trial)</title>
          <description>Insulin level 30 minutes after consuming 75 grams of glucose</description>
          <population>Descriptive data, reflecting participant flow Pre-weight loss (N=162, minus 1 participant in the Moderate carbohydrate diet group for whom insulin-30 result is missing) Start of trial (N=162) End of test phase (N=148, minus 1 participant in the High carbohydrate diet group for whom insulin-30 result is missing)</population>
          <units>mIU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-weight loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.4" lower_limit="77.6" upper_limit="173.5"/>
                    <measurement group_id="O2" value="116.7" lower_limit="86.8" upper_limit="218.5"/>
                    <measurement group_id="O3" value="99.2" lower_limit="73.7" upper_limit="153.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of trial</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="55.5" upper_limit="131.3"/>
                    <measurement group_id="O2" value="79.9" lower_limit="56.1" upper_limit="143.3"/>
                    <measurement group_id="O3" value="68.0" lower_limit="57.0" upper_limit="106.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of test phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="50.5" upper_limit="134.0"/>
                    <measurement group_id="O2" value="74.5" lower_limit="51.3" upper_limit="135.4"/>
                    <measurement group_id="O3" value="74.8" lower_limit="53.1" upper_limit="109.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect Modification by Insulin Secretion of Metabolic Responses to Diet</title>
        <description>Effect modifier: Insulin level 30 minutes into an standard OGTT (Insulin-30) Outcome: Total Energy Expenditure Tertiles: Pre-weight-loss Insulin-30 (Low, Moderate, High) Change: average (midpoint of test phase, end of test phase) - start of trial</description>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <population>The outcome is &quot;Effect Modification by Insulin Secretion.&quot; Thus,participants were divided into tertiles of Insulin-30.&#xD;
Tertile I: Low=17, Moderate=16, High=22 Tertile II: Low=15, Moderate=22, High=17 Tertile III: Low=24, Moderate=14, High=15</population>
        <group_list>
          <group group_id="O1">
            <title>Low Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O2">
            <title>Moderate Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
          <group group_id="O3">
            <title>High Carbohydrate Diet</title>
            <description>Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein&#xD;
Feeding study: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Modification by Insulin Secretion of Metabolic Responses to Diet</title>
          <description>Effect modifier: Insulin level 30 minutes into an standard OGTT (Insulin-30) Outcome: Total Energy Expenditure Tertiles: Pre-weight-loss Insulin-30 (Low, Moderate, High) Change: average (midpoint of test phase, end of test phase) - start of trial</description>
          <population>The outcome is &quot;Effect Modification by Insulin Secretion.&quot; Thus,participants were divided into tertiles of Insulin-30.&#xD;
Tertile I: Low=17, Moderate=16, High=22 Tertile II: Low=15, Moderate=22, High=17 Tertile III: Low=24, Moderate=14, High=15</population>
          <units>kcal/d</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Trial, Low Insulin-30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2795" lower_limit="2591" upper_limit="2998"/>
                    <measurement group_id="O2" value="2673" lower_limit="2456" upper_limit="2891"/>
                    <measurement group_id="O3" value="2647" lower_limit="2463" upper_limit="2832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, Low Insulin-30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" lower_limit="-1" upper_limit="295"/>
                    <measurement group_id="O2" value="103" lower_limit="-44" upper_limit="250"/>
                    <measurement group_id="O3" value="15" lower_limit="-119" upper_limit="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Trial, Moderate Insulin-30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2816" lower_limit="2597" upper_limit="3035"/>
                    <measurement group_id="O2" value="2563" lower_limit="2377" upper_limit="2750"/>
                    <measurement group_id="O3" value="2782" lower_limit="2571" upper_limit="2993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, Moderate Insulin-30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="-37" upper_limit="266"/>
                    <measurement group_id="O2" value="-5" lower_limit="-136" upper_limit="127"/>
                    <measurement group_id="O3" value="-50" lower_limit="-200" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Trial, High Insulin-30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2643" lower_limit="2461" upper_limit="2826"/>
                    <measurement group_id="O2" value="2281" lower_limit="2053" upper_limit="2508"/>
                    <measurement group_id="O3" value="2544" lower_limit="2331" upper_limit="2757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change, High Insulin-30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271" lower_limit="145" upper_limit="396"/>
                    <measurement group_id="O2" value="141" lower_limit="-20" upper_limit="303"/>
                    <measurement group_id="O3" value="-37" lower_limit="-201" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect Modification by Insulin Resistance of Metabolic Responses to Diet</title>
        <time_frame>Start of (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect Modification by Amylase Gene Copy Number</title>
        <time_frame>Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance</time_frame>
        <posting_date>12/2025</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the run-in diet (~12 weeks) and the test diet (20 weeks) periods of the study, a total of ~32 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Run-in Phase</title>
          <description>Pre-randomization: During the run-in phase, energy intake was restricted to promote 12% (within 2%) weight loss over 9-10 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Low Carbohydrate Diet</title>
          <description>Feeding study: Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein.</description>
        </group>
        <group group_id="E3">
          <title>Moderate Carbohydrate Diet</title>
          <description>Feeding study: Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein.</description>
        </group>
        <group group_id="E4">
          <title>High Carbohydrate Diet</title>
          <description>Feeding study: Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Removal of intrauterine device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Laparoscopic cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Possible hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mood changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Possible gall bladder disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hypertension (new prescription medication)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy, aversion or intolerance</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased blood cholesterol</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Possible post-viral lactose intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Ankle sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tested to rule out meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>High blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study has three main limitations: potential measurement error, non-compliance, and generalizability.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cara Ebbeling, PhD, Co-Director, New Balance Foundation Obesity Prevention Center</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <phone>617-919-3457</phone>
      <email>Cara.Ebbeling@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

